Intratracheal administration of hUCMSC-derived EVs ameliorated severe, steroid-resistant asthma in a mouse model by moderating inflammation, which is achieved by reshaping macrophage polarization via inhibition of TRAF1. Here, TRAF1 is linked to asthma.